# Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

> **NCT07471776** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 45 (estimated)

## Conditions studied

- Metastatic Breast Cancer ( HER2 Negative)

## Interventions

- **DRUG:** Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan
- **DIAGNOSTIC_TEST:** 68Ga-TROP2 PET/CT Imaging
- **DIAGNOSTIC_TEST:** 18F-FDG PET Imaging

## Key facts

- **NCT ID:** NCT07471776
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2028-03-11
- **Final completion:** 2029-03-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471776, "Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07471776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*